Hormonal control of p53 and chemoprevention
Improvements in the detection and treatment of breast cancer have dramatically altered its clinical course and outcome. However, prevention of breast cancer remains an elusive goal. Parity, age of menarche, and age at menopause are major risk factors drawing attention to the important role of the en...
Main Authors: | Jerry, D Joseph, Minter, Lisa M, Becker, Klaus A, Blackburn, Anneke C |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2002
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138728/ |
Similar Items
-
Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?
by: Blackburn, Anneke C, et al.
Published: (2002) -
Chemoprevention with the metabolism modifying drugs dichloroacetate and metformin in the Li-Fraumeni Syndrome model, Trp53+/- mice
by: Blackburn, Anneke C, et al.
Published: (2014) -
Chemoprevention with the metabolism modifying drugs dichloroacetate and metformin in Trp53+/- mice
by: Blackburn, AC, et al.
Published: (2012) -
Adherence to hormone therapy in a chemoprevention randomised trial
by: Atkins, L, et al.
Published: (2008) -
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism
by: Pal, Srabani, et al.
Published: (2014)